| Identification | Back Directory | [Name]
Indazolo(4,3-gh)isoquinolin-6(2H)-one, 2-(2-((2-hydroxyethyl)amino)ethyl)-5-((2-(methylamino)ethyl)amino)-, dihydrochloride | [CAS]
438244-41-8 | [Synonyms]
BBR3438
BBR-3438
Nortopixantrone HCl
Nortopixantrone hydrochloride
Indazolo(4,3-gh)isoquinolin-6(2H)-one, 2-(2-((2-hydroxyethyl)amino)ethyl)-5-((2-(methylamino)ethyl)amino)-, dihydrochloride | [Molecular Formula]
C20H26Cl2N6O2 | [MOL File]
438244-41-8.mol | [Molecular Weight]
453.365 |
| Hazard Information | Back Directory | [Description]
Nortopixantrone, also known as BBR-3438, is a DNA topoisomerase inhibitor potentially for thetreatment of gastric cancer, ovarian cancer. BR 3438 exhibited a unique profile of preclinical activity with a superior efficacy against prostatic carcinoma models compared to reference compounds (doxorubicin and losoxantrone). The antitumour efficacy of BBR 3438 against prostatic carcinoma could be the result of a combination of favourable events, including enhanced intracellular accumulation and an increased DNA-binding affinity favouring the accumulation of multiple sublethal or lethal damage. | [Uses]
Nortopixantrone dihydrochloride (BBR 3438) is a 9-aza-anthrapyrazole-based antineoplastic antibiotic. Nortopixantrone dihydrochloride plays an important role in cacner research[1]. | [References]
[1] R-D Hofheinz, et al. BBR 3438, a novel 9-aza-anthrapyrazole, in patients with advanced gastric cancer: a phase II study group trial of the Central European Society of Anticancer-Drug Research (CESAR). Clinical Trial Invest New Drugs. 2005 Aug;23(4):363-8. DOI:10.1007/s10637-005-1445-z |
|
|